Business
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody(TM) ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs ...
About this update from Bolt Metals Corp.
[{"type":"text","content":"Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025\n\n\n\n\n CEA-targeted\n \n\n ISAC\n \n\n elicits complete responses in mice and is well-tolerated in NHPs\n \n\n\n\n PD-L1 ISAC\n \n\n directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory\n \n\n\n REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced preclinical results from its next-generation Boltbody™ ISACs targeting CEACAM5 and PD-L1 at the American Association for Cancer Research (AACR) Annual Meeting.\n \n\n “We are encouraged by these early results from our next-generation Boltbody™ ISACs targeting CEA and PD-L1,” said Michael Alonso, Ph.D., Senior Vice President of Research. “There are currently no approved therapies targeting CEA, and our next-gen CEA ISAC induced complete and durable anti-tumor responses in mice and was well-tolerated in NHPs. Additionally, the preclinical results demonstrated that PD-L1 ISACs represent a compelling new approach to treat cancer, leveraging mechanisms that are distinct from and potentially complementary to conventional PD-1/PD-L1 blockade.”\n \n\n CEA refers to a specific carcinoembryonic antigen cell adhesion molecule also known as CEACAM-5 that is commonly found in gastrointestinal cancers such as colorectal cancer. Bolt’s lead CEA-targeted ISAC comprises a novel, fully human antibody with high affinity and selectivity to CEA, and not to other members of the CEACAM family, conjugated to a proprietary next-generation TLR7/8 agonist via a non-cleavable linker. This ISAC drives enhanced phagocytosis of CEA-positive tumor cells and stimulates production of critical immune-activating cytokines including IL-12p70, IFNg, and TNFa. Key results with the next-gen CEA ISAC are below:\n \n\n\n Antigen-dependent induction of immune-stimulating cytokines in human, NHP and mouse effector cells\n \n\n Complete responses in CEA transgenic syngeneic model demonstrates robust efficacy\n \n\n Induction of immunological memory demonstrates potential for durable responses\n \n\n In ...